



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Tebentafusp

Cat. No.:	HY-P99339
CAS No.:	1874157-95-5
Target:	Interleukin Related; TNF Receptor
Pathway:	Immunology/Inflammation; Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Tebentafusp (IMCgp100) is a bispecific fusion protein to target gp100 peptide-HLA-A*02:01 (a melanoma-associated antigen). Tebentafusp guides T cells to kill gp100-expressing tumor cells via a high affinity T-cell receptor (TCR) binding domain and an anti-CD3 T-cell engaging domain. Tebentafusp leads to inflammatory cytokines and cytolytic proteins production, resulting in the direct lysis of tumour cells ^{[1][2]} .
In Vitro	<p>Tebentafusp is an ImmTAC recognizing a peptide derived from the melanoma-specific protein, gp100, presented by HLA-A*0201^[3].</p> <p>Tebentafusp (31 pM, 82 pM, and 131 pM; 16 h) stimulates cytotoxic degranulation activity of PBMC against Mel526 cells rather than gp100-negative A375 cells^[3].</p> <p>Tebentafusp (100 pM; 0-50 h) mediates CD8⁺ T cell killing despite the presence of regulatory T cells via monitoring caspase 3/7 activation during 40-48 hr^[3].</p> <p>Tebentafusp (100 pM; 0-80 h) triggers cytolysis of melanoma cells by CD4⁺ T cell subpopulations^[3].</p> <p>Tebentafusp (1, 12, 31, 82, and 131 pM; 24 h or 96 h) increases granzyme B amount, and induces broad cytokine and chemokine release including in both CD4⁺ and CD8⁺ cells^[3].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>
In Vivo	<p>Tebentafusp (10 µg/kg; i.v.) inhibits tumor growth in mouse melanoma model^[4].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

REFERENCES

- [1]. Middleton MR, et al. Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma. *Clin Cancer Res.* 2020 Nov 15;26(22):5869-5878.
- [2]. Dhillon S. Tebentafusp: First Approval. *Drugs.* 2022 Apr;82(6):703-710.
- [3]. Boudousquie C, et al. Polyfunctional response by ImmTAC (IMCgp100) redirected CD8⁺ and CD4⁺ T cells. *Immunology.* 2017 Nov;152(3):425-438.
- [4]. Baeuerle P A, et al. Passive immunotherapy by T cell-engaging bispecific antibodies[M]//Cancer Vaccines. CRC Press, 2015: 266-278.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA